Abstract
The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Current HIV Research
Title: HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Volume: 9 Issue: 4
Author(s): Shiguan Lin, Yuhao Zhang, Hao Ying and Huanzhang Zhu
Affiliation:
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Abstract: The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Export Options
About this article
Cite this article as:
Lin Shiguan, Zhang Yuhao, Ying Hao and Zhu Huanzhang, HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells, Current HIV Research 2011; 9 (4) . https://dx.doi.org/10.2174/157016211796320333
DOI https://dx.doi.org/10.2174/157016211796320333 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Current Drug Targets Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Prediction and Identification of Krüppel-Like Transcription Factors by Machine Learning Method
Combinatorial Chemistry & High Throughput Screening Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism